Mantle Cell Lymphoma | Specialty

Dr. Hamlin on Toxicities Associated With Ibrutinib and Buparlisib in MCL, FL, and DLBCL

August 10th 2017

Paul A. Hamlin, MD, of Memorial Sloan Kettering Cancer Center, discusses the toxicities reported in a phase I dose-escalation study of buparlisib plus ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Dr. Martin on ASCT-Related Toxicities for Patients With MCL

August 8th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the toxicities related to stem cell transplantation for patients with mantle cell lymphoma (MCL).

MRD Associated With Poorer Survival Following ASCT in MCL

August 7th 2017

Long-term results from the Nordic MCL2 and MCL3 trials showed patients with mantle cell lymphoma who are positive for minimal residual disease following allogenic stem cell transplant had significantly shorter survival.

Dr. Leonard on Exciting Advancements in the Field of Mantle Cell Lymphoma

August 7th 2017

John P. Leonard, MD, professor of Medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses some of the exciting advancements taking place in the field of mantle cell lymphoma (MCL).

FDA Awards Acalabrutinib Priority Review in MCL

August 2nd 2017

The FDA has granted a priority review to a new drug application for acalabrutinib for patients with previously-treated mantle cell lymphoma.

FDA Grants Acalabrutinib Breakthrough Designation in MCL

August 2nd 2017

The FDA has granted acalabrutinib a breakthrough therapy designation for patients with previously-treated mantle cell lymphoma.

Dr. Nowakowski on the Potential Role of Immunotherapy in MCL

August 1st 2017

Grzegorz S. Nowakowski, MD, assistant professor of medicine at Mayo Clinic, discusses what potential immunotherapy agents have in the treatment landscape of mantle cell lymphoma (MCL).

Emerging Agents for Mantle Cell Lymphoma

July 26th 2017

Acalabrutinib for Treating Mantle Cell Lymphoma

July 26th 2017

Ongoing Challenges in Treating Mantle Cell Lymphoma

July 26th 2017

Treating Relapsed/Refractory Mantle Cell Lymphoma

July 26th 2017

Role of Maintenance Therapy in Mantle Cell Lymphoma

July 26th 2017

Response Assessment in Mantle Cell Lymphoma

July 26th 2017

Options for Upfront Therapy in MCL

July 26th 2017

Induction Therapy for MCL

July 26th 2017

Risk Assessment and Prognosis in MCL

July 26th 2017

Biology of Mantle Cell Lymphoma

July 26th 2017

Mantle Cell Lymphoma: Evolution of Therapy

July 26th 2017

Dr. Shah on Emerging Developments in MCL

July 24th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses some of the emerging developments on the horizon in mantle cell lymphoma (MCL).

Bendamustine Plus Rituximab Maintains Frontline PFS Benefit in MCL, iNHL After 5 Years

July 17th 2017

Five-year follow-up from the BRIGHT study confirmed that bendamustine plus rituximab is associated with improved progression-free survival compared with R-CHOP or R-CVP in patients with mantle cell lymphoma or indolent non-Hodgkin lymphoma.